Sort   by:  
 Page size 
UnknownEffectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Not available
S-EPMC9609988 | biostudies-literature
UnknownDigital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Not available
S-EPMC8491983 | biostudies-literature
UnknownPresence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.
Not available
S-EPMC11868123 | biostudies-literature
UnknownNF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Not available
S-EPMC9431958 | biostudies-literature
UnknownTERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Not available
S-EPMC9431961 | biostudies-literature
UnknownDiscontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Not available
S-EPMC8151093 | biostudies-literature
UnknownCorrelation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Not available
S-EPMC10483509 | biostudies-literature
Sort   by:  
 Page size